Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Schering GMP investigation

  • News

Executive Summary

The Newark, N.J. U.S. Attorney's Office is spearheading a criminal investigation related to Schering-Plough's Puerto Rico production facilities, Schering confirms (1"The Pink Sheet" May 20, p. 5). The investigation reportedly focuses on use of unapproved raw materials...

You may also be interested in...



Schering GMP investigation closed

Newark U.S. attorney's office has closed an investigation on Schering's Puerto Rico manufacturing facility. The inquiry, which was announced in May 2002, focused on the use of unapproved raw materials (1"The Pink Sheet" May 20, 2002, In Brief)...

Schering GMP investigation

FDA/Justice Department investigation of Schering-Plough's GMP compliance at its Manati, P.R. facility is focusing on ribavirin, among other products, firm discloses. The investigation itself was disclosed in May; Schering has not previously identified specific products targeted (1"The Pink Sheet" June 24, 2002, In Brief)...

Schering GMP Criminal Investigation Continues After Consent Decree

Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17
Table

View full table

Tags:
UsernamePublicRestriction

Register

PS040063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By